References:
1. Sherman, P.M., et al., Probiotics reduce enterohemorrhagic Escherichia coli O157:H7- and enteropathogenic E. coli O127:H6-induced changes in polarized T84 epithelial cell monolayers by reducing bacterial adhesion and cytoskeletal rearrangements. Infect Immun, 2005. 73(8): p. 5183-8.
2. Firmesse, O., et al., Lactobacillus rhamnosus R11 consumed in a food supplement survived human digestive transit without modifying microbiota equilibrium as assessed by real-time polymerase chain reaction. J Mol Microbiol Biotechnol, 2008. 14(1-3): p. 90-9.
3. WALLACE, D., et al., Interactions of Lactic Acid Bacteria with Human Intestinal Epithelial Cells: Effects on Cytokine Production. Journal of Food Protection, 2003. Vol. 66, No. 3, 2003, Pages 466–472.
4. Foster, L.M., T.A. Tompkins, and W.J. Dahl, A comprehensive post-market review of studies on a probiotic product containing Lactobacillus helveticus R0052 and Lactobacillus rhamnosus R0011. Benef Microbes, 2011. 2(4): p. 319-34.
5. Johnson-Henry, K.C., et al., Surface-layer protein extracts from Lactobacillus helveticus inhibit enterohaemorrhagic Escherichia coli O157:H7 adhesion to epithelial cells. Cell Microbiol, 2007. 9(2): p. 356-67.
6. Crittenden, R.G., et al., Selection of a Bi®dobacterium strain to complement resistant starch in a synbiotic yoghurt. Journal of Applied Microbiology, 2001. 2001, 90, 268±278.
7. Basturk, A., R. Artan, and A. Yilmaz, Efficacy of synbiotic, probiotic, and prebiotic treatments for irritable bowel syndrome in children: A randomized controlled trial. Turk J Gastroenterol, 2016. 27(5): p. 439-443.
8. Islek, A., et al., The role of Bifidobacterium lactis B94 plus inulin in the treatment of acute infectious diarrhea in children. Turk J Gastroenterol, 2014. 25(6): p. 628-33.
9. Wallace, C.J.K. and R.V. Milev, The Efficacy, Safety, and Tolerability of Probiotics on Depression: Clinical Results From an Open-Label Pilot Study. Front Psychiatry, 2021. 12: p. 618279.
10. Messaoudi, M., et al., Beneficial psychological effects of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in healthy human volunteers. Gut Microbes, 2011. 2(4): p. 256-61.